The Scientific Advisory Board of DSEF has formulated their latest recommendations on the COVID-19 vaccination across Dravet Syndrome population.

Although for the moment, there are still no definitive answers neither concerning the impact of the disease nor of the vaccination, it seems however that most experts agree that for people with epilepsy, the risk of COVID-19 infection and potential complications outweighs the risk of side effects from a COVID-19 vaccine.

Another open topic remains if the use of a vaccine utilising an adeno virus carrier could preclude future genetic therapies that may use the same adenovirus, at this stage the assessment of the first COVID-19 vaccines based on adenoviral vectors being still under investigation.

Please feel free to share this document with whomever you consider interested.

More information about the Scientific Advisory Board is available here.